Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Hisse Senetlerindeki Sıralama #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Hisse Fiyatı
$4.74
Son senkronizasyon: 2026-08-31
Piyasa Değeri
$372.19M
Değişim (1 gün)
-2.47%
Değişim (1 yıl)
-1.04%
Ülke
US
Ticaret Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategori

Lexeo Therapeutics, Inc. Common Stock (LXEO) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $4.91 - 2026-08-01

Gün sonu en düşük fiyat: $11.06 - 2023-11-01
Lexeo Therapeutics, Inc. Common Stock için hisse fiyatı geçmişi: 2023 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.74 4.52%
CH